◎ Sugi Atlas

Atlas / Gene / UNC13C

UNC13C

gene
On this page

Also known as Munc13-3DKFZp547H074

Summary

UNC13C (unc-13 homolog C, HGNC:23149) is a protein-coding gene on chromosome 15q21.3, encoding Protein unc-13 homolog C (Q8NB66). May play a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway.

Predicted to enable calmodulin binding activity and syntaxin-1 binding activity. Predicted to be involved in glutamatergic synaptic transmission and regulated exocytosis. Predicted to be located in presynaptic active zone. Predicted to be active in several cellular components, including axon terminus; parallel fiber to Purkinje cell synapse; and synaptic vesicle membrane.

Source: NCBI Gene 440279 — RefSeq curated summary.

At a glance

  • GWAS associations: 18
  • Clinical variants (ClinVar): 329 total
  • Phenotypes (HPO): 1
  • MANE Select transcript: NM_001080534

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:23149
Approved symbolUNC13C
Nameunc-13 homolog C
Location15q21.3
Locus typegene with protein product
StatusApproved
AliasesMunc13-3, DKFZp547H074
Ensembl geneENSG00000137766
Ensembl biotypeprotein_coding
OMIM614568
Entrez440279

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000260323, ENST00000539562, ENST00000559093, ENST00000560537, ENST00000561210, ENST00000647821

RefSeq mRNA: 2 — MANE Select: NM_001080534 NM_001080534, NM_001329919

CCDS: CCDS45264, CCDS92002

Canonical transcript exons

ENST00000260323 — 33 exons

ExonStartEnd
ENSE000006897655425022554250444
ENSE000006897675426416854264395
ENSE000009418965449460854494734
ENSE000009418975450007954500175
ENSE000009418985450083554500978
ENSE000009419015454672254546845
ENSE000010003135450711754507194
ENSE000010003165452554954525637
ENSE000010003215453291754533066
ENSE000011863985423761954237690
ENSE000011864055423503054235108
ENSE000012471275456780054567947
ENSE000012471345455543254555512
ENSE000012471405454963554549691
ENSE000017241325414301854143040
ENSE000017963025423643054236435
ENSE000018007675414362054143684
ENSE000018064195451175354511830
ENSE000025660515462682854628605
ENSE000034784785429389554294064
ENSE000034892905426535554265496
ENSE000034924785433204354332111
ENSE000034981845432193954322095
ENSE000035034125441498254415067
ENSE000035290845462232754622419
ENSE000035393355433836154338489
ENSE000035534135439304854393181
ENSE000035843085462379554623954
ENSE000036048755430021054300373
ENSE000036116375433376754333856
ENSE000036836945429781154297926
ENSE000038400305401264854015886
ENSE000039198505397844153978927

Expression profiles

Bgee: expression breadth ubiquitous, 174 present calls, max score 99.53.

FANTOM5 (CAGE): breadth broad, TPM avg 3.3901 / max 920.6575, expressed in 184 samples.

FANTOM5 promoters (15 alternative TSS)

Promoter IDTPM avgSamples expressed
1467431.2173132
1467390.482097
1467450.389288
1467360.267079
1467380.254984
1467370.244480
1467460.166862
1467400.148762
1467470.058623
1467480.039610

Top tissues by expression

237 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
secondary oocyteCL:000065599.53gold quality
oocyteCL:000002399.43gold quality
endothelial cellCL:000011598.96gold quality
substantia nigra pars reticulataUBERON:000196697.92gold quality
substantia nigra pars compactaUBERON:000196597.82gold quality
cerebellar vermisUBERON:000472094.98gold quality
ponsUBERON:000098893.91gold quality
primary visual cortexUBERON:000243693.53gold quality
cerebellumUBERON:000203793.40gold quality
cerebellar cortexUBERON:000212993.15gold quality
cerebellar hemisphereUBERON:000224593.03gold quality
Brodmann (1909) area 23UBERON:001355492.93gold quality
occipital lobeUBERON:000202192.43gold quality
right hemisphere of cerebellumUBERON:001489091.60gold quality
amygdalaUBERON:000187691.28gold quality
anterior cingulate cortexUBERON:000983591.25gold quality
Brodmann (1909) area 46UBERON:000648391.06gold quality
right frontal lobeUBERON:000281090.98gold quality
superior frontal gyrusUBERON:000266190.18gold quality
postcentral gyrusUBERON:000258189.61gold quality
dorsolateral prefrontal cortexUBERON:000983489.60gold quality
parietal lobeUBERON:000187289.34gold quality
temporal lobeUBERON:000187189.16gold quality
neocortexUBERON:000195089.15gold quality
frontal cortexUBERON:000187088.95gold quality
prefrontal cortexUBERON:000045187.46gold quality
middle temporal gyrusUBERON:000277187.24gold quality
cerebral cortexUBERON:000095687.18gold quality
entorhinal cortexUBERON:000272886.46gold quality
midbrainUBERON:000189186.05gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

ExperimentMarker?Max mean expression
E-CURD-11yes27.67
E-HCAD-25yes9.00
E-ANND-3yes7.29
E-MTAB-8060no255.72

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 2)

  • Circ-KIAA0907 inhibits the progression of oral squamous cell carcinoma by regulating the miR-96-5p/UNC13C axis. (PMID:33715625)
  • Prognostic and Clinical Implications of UNC13C expression in Hepatocellular Carcinoma Patients. (PMID:37575271)

Cross-species orthologs

3 orthologs

OrganismSymbolGene ID
danio_reriounc13cENSDARG00000112435
mus_musculusUnc13cENSMUSG00000062151
rattus_norvegicusUnc13cENSRNOG00000056612

Paralogs (2): UNC13A (ENSG00000130477), UNC13B (ENSG00000198722)

Protein

Protein identifiers

Protein unc-13 homolog C — Q8NB66 (reviewed: Q8NB66)

Alternative names: Munc13-3

All UniProt accessions (5): Q8NB66, A0A0C4DGH4, A0A3B3ISZ1, H0YL13, H3BRP8

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in vesicle maturation during exocytosis as a target of the diacylglycerol second messenger pathway. May be involved in the regulation of synaptic transmission at parallel fiber - Purkinje cell synapses.

Subunit / interactions. Interacts with STX1A and/or STX1B1, VAMP2 and SNAP25.

Subcellular location. Cytoplasm. Membrane. Presynaptic cell membrane.

Tissue specificity. Exclusively expressed in brain.

Domain organisation. The C2 domains are not involved in calcium-dependent phospholipid binding.

Similarity. Belongs to the unc-13 family.

RefSeq proteins (2): NP_001074003, NP_001316848 (=MANE)

Domains & families (InterPro)

IDNameType
IPR000008C2_domDomain
IPR002219PKC_DAG/PEDomain
IPR010439MUN_domDomain
IPR014770Munc13_1Domain
IPR014772Munc13_dom-2Domain
IPR027080Unc-13Family
IPR035892C2_domain_sfHomologous_superfamily
IPR037302Unc-13_C2BDomain
IPR046349C1-like_sfHomologous_superfamily

Pfam: PF00130, PF00168, PF06292

UniProt features (39 total): binding site 8, region of interest 7, compositionally biased region 7, domain 4, modified residue 4, sequence variant 4, coiled-coil region 2, chain 1, sequence conflict 1, zinc finger region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-Q8NB66-F161.640.18

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 1236; 1236; 1242; 1288; 1288; 1290; 1290; 1307

Post-translational modifications (4): 89, 448, 452, 788

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 129 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GOBP_VESICLE_LOCALIZATION, GOBP_NEUROTRANSMITTER_TRANSPORT, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_CELL_CELL_SIGNALING, GOBP_MEMBRANE_DOCKING, GOBP_EXOCYTOSIS, GOBP_REGULATION_OF_SYNAPTIC_PLASTICITY, GOBP_VESICLE_DOCKING_INVOLVED_IN_EXOCYTOSIS, GOBP_SECRETION, GOBP_SIGNAL_RELEASE, GOBP_CALCIUM_ION_REGULATED_EXOCYTOSIS, GOBP_SYNAPTIC_SIGNALING, GOCC_NEURON_PROJECTION, GOBP_SYNAPTIC_TRANSMISSION_GLUTAMATERGIC

GO Biological Process (8): chemical synaptic transmission (GO:0007268), obsolete synaptic vesicle docking (GO:0016081), synaptic vesicle priming (GO:0016082), negative regulation of synaptic plasticity (GO:0031914), synaptic transmission, glutamatergic (GO:0035249), dense core granule priming (GO:0061789), exocytosis (GO:0006887), synaptic vesicle exocytosis (GO:0016079)

GO Molecular Function (7): calcium ion binding (GO:0005509), calmodulin binding (GO:0005516), phospholipid binding (GO:0005543), zinc ion binding (GO:0008270), syntaxin-1 binding (GO:0017075), diacylglycerol binding (GO:0019992), metal ion binding (GO:0046872)

GO Cellular Component (13): plasma membrane (GO:0005886), synaptic vesicle membrane (GO:0030672), neuromuscular junction (GO:0031594), presynaptic membrane (GO:0042734), terminal bouton (GO:0043195), calyx of Held (GO:0044305), presynaptic active zone (GO:0048786), parallel fiber to Purkinje cell synapse (GO:0098688), cytoplasm (GO:0005737), membrane (GO:0016020), cell projection (GO:0042995), synapse (GO:0045202), presynapse (GO:0098793)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
cellular anatomical structure5
presynapse4
protein-containing complex assembly2
exocytic process2
lipid binding2
synapse2
axon terminus2
anterograde trans-synaptic signaling1
synaptic vesicle exocytosis1
regulation of synaptic plasticity1
chemical synaptic transmission1
dense core granule exocytosis1
vesicle-mediated transport1
secretion by cell1
vesicle fusion to plasma membrane1
neurotransmitter secretion1
regulated exocytosis1
establishment of localization in cell1
vesicle-mediated transport in synapse1
synaptic vesicle cycle1
signal release from synapse1
metal ion binding1
protein binding1
transition metal ion binding1
syntaxin binding1
cation binding1
membrane1
cell periphery1
synaptic vesicle1
exocytic vesicle membrane1
synaptic membrane1
excitatory synapse1
intracellular anatomical structure1
cell junction1

Protein interactions and networks

STRING

1222 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
UNC13CCOL4A1P02462636
UNC13CSTXBP1P61764633
UNC13CRAB34Q9BZG1554
UNC13CRIMS1Q86UR5514
UNC13CSNAP25P13795493
UNC13CCADM2Q8N3J6437
UNC13CRIMBP2O15034435
UNC13CZFHX4Q86UP3418
UNC13CCAMK2N2Q96S95414
UNC13CST3GAL3Q11203409
UNC13CERC1Q8IUD2406
UNC13CCAMK1GQ96NX5404
UNC13CTRPM3Q9HCF6398
UNC13CSYT1P21579397
UNC13CRIMS2Q9UQ26396

IntAct

4 interactions, top by confidence:

ABTypeScore
UNC13CPRKCSHpsi-mi:“MI:0915”(physical association)0.400
UNC13CH1-1psi-mi:“MI:0915”(physical association)0.400
UNC13CRPLP2psi-mi:“MI:0915”(physical association)0.400

BioGRID (13): UNC13C (Proximity Label-MS), UNC13C (Proximity Label-MS), UNC13C (Proximity Label-MS), UNC13C (Affinity Capture-MS), UNC13C (Cross-Linking-MS (XL-MS)), UNC13C (Cross-Linking-MS (XL-MS)), SEPT7 (Cross-Linking-MS (XL-MS)), ANXA5 (Cross-Linking-MS (XL-MS)), HSP90AA1 (Cross-Linking-MS (XL-MS)), HSP90AB1 (Cross-Linking-MS (XL-MS)), UNC13C (Affinity Capture-MS), UNC13C (Cross-Linking-MS (XL-MS)), UNC13C (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A140LFM6, A0A1L8H8C0, A0A1L8HFX9, A0A2R6X6S3, A0JM08, A2ARZ3, A2RUV4, A5WUN7, A6QP06, D4AEC2, E9Q309, O76039, P51960, Q03898, Q05935, Q06190, Q08AD1, Q08D57, Q0WPH8, Q3KQW7, Q3UTQ8, Q498L0, Q5RAU1, Q5SW79, Q5T0W9, Q5T5U3, Q5VT06, Q62770, Q66J90, Q69Z38, Q6A065, Q6DFG0, Q6DFV3, Q6IRN6, Q71M21, Q80TN7, Q8AV28, Q8C1B1, Q8IVL0, Q8IZ21

Diamond homologs: A0A075F932, A0FGR8, A0FGR9, A1ZBD6, A8KBH6, D4ABL6, K8FE10, O00443, O00750, O08835, O35681, O43581, P13677, P21521, P21579, P21707, P24506, P24507, P27715, P29101, P34693, P40748, P40749, P41823, P41885, P46096, P46097, P47191, P47708, P47709, P48018, P50232, P70169, P70610, P97610, Q06846, Q14183, Q14184, Q15811, Q3TZZ7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

329 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic0
Uncertain significance304
Likely benign11
Benign0

Top pathogenic / likely-pathogenic (0)

SpliceAI

6591 predictions. Top by Δscore:

VariantEffectΔscore
15:54235025:TTCA:Tacceptor_loss1.0000
15:54235027:CA:Cacceptor_loss1.0000
15:54235028:A:AGacceptor_gain1.0000
15:54235028:AG:Aacceptor_gain1.0000
15:54235028:AGG:Aacceptor_gain1.0000
15:54235029:G:GAacceptor_gain1.0000
15:54235029:GG:Gacceptor_gain1.0000
15:54235029:GGG:Gacceptor_gain1.0000
15:54235029:GGGCT:Gacceptor_gain1.0000
15:54235104:ATGTG:Adonor_gain1.0000
15:54235106:GTG:Gdonor_gain1.0000
15:54235107:TG:Tdonor_gain1.0000
15:54235108:GG:Gdonor_gain1.0000
15:54235109:G:GGdonor_gain1.0000
15:54235110:T:Gdonor_loss1.0000
15:54237613:TTTTA:Tacceptor_loss1.0000
15:54237614:TTTA:Tacceptor_loss1.0000
15:54237615:TTAGA:Tacceptor_loss1.0000
15:54237616:TAG:Tacceptor_loss1.0000
15:54237617:A:AGacceptor_gain1.0000
15:54237617:A:Tacceptor_loss1.0000
15:54237618:G:GGacceptor_gain1.0000
15:54237618:GA:Gacceptor_gain1.0000
15:54237618:GACC:Gacceptor_gain1.0000
15:54237687:ACTGG:Adonor_loss1.0000
15:54237689:TGG:Tdonor_loss1.0000
15:54237691:G:GGdonor_gain1.0000
15:54237691:GTAA:Gdonor_loss1.0000
15:54237692:TAAG:Tdonor_loss1.0000
15:54238553:G:GTdonor_gain1.0000

AlphaMissense

14733 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
15:54013652:T:CL250P1.000
15:54013691:T:CL263P1.000
15:54250327:T:CC1111R1.000
15:54250329:T:GC1111W1.000
15:54265373:T:CL1232P1.000
15:54265406:C:AP1243Q1.000
15:54265412:T:AV1245D1.000
15:54265418:T:AV1247D1.000
15:54265477:T:AW1267R1.000
15:54265477:T:CW1267R1.000
15:54265479:G:CW1267C1.000
15:54265479:G:TW1267C1.000
15:54293927:T:AV1284D1.000
15:54293935:T:AW1287R1.000
15:54293935:T:CW1287R1.000
15:54293937:G:CW1287C1.000
15:54293937:G:TW1287C1.000
15:54293998:T:CF1308L1.000
15:54294000:T:AF1308L1.000
15:54294000:T:GF1308L1.000
15:54294004:G:AG1310R1.000
15:54294004:G:CG1310R1.000
15:54294062:T:CL1329S1.000
15:54297840:G:AG1340R1.000
15:54297840:G:CG1340R1.000
15:54297840:G:TG1340W1.000
15:54297841:G:AG1340E1.000
15:54297847:T:AI1342K1.000
15:54322004:T:CL1445P1.000
15:54333825:T:CL1518P1.000

dbSNP variants (sampled 300 via entrez): RS1000000787 (15:54371117 C>A,T), RS1000014377 (15:54424006 T>A,C), RS1000015527 (15:54588246 C>A,T), RS1000016468 (15:54220545 A>G), RS1000028483 (15:54326275 G>A), RS1000031941 (15:54121638 T>G), RS1000032953 (15:53936193 T>C), RS1000036738 (15:54151319 A>G), RS1000037473 (15:54293166 A>G), RS1000039689 (15:54298183 A>T), RS1000045402 (15:54550772 T>G), RS1000050206 (15:54186364 G>A), RS1000051676 (15:54600034 T>A,C), RS1000054504 (15:54442729 G>A), RS1000055634 (15:54482936 A>G)

Disease associations

OMIM: gene MIM:614568 | disease phenotypes: MIM:119800

GenCC curated gene-disease

Mondo (3): Alzheimer disease (MONDO:0004975), cystic kidney disease (MONDO:0002473), clubfoot (MONDO:0007342)

Orphanet (3): Early-onset autosomal dominant Alzheimer disease (Orphanet:1020), Familial clubfoot with or without associated lower limb anomalies (Orphanet:199315), NON RARE IN EUROPE: Alzheimer disease (Orphanet:238616)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPOTerm
HP:0002511Alzheimer disease

GWAS associations

18 associations (top):

StudyTraitp-value
GCST000477_58Cognitive performance1.000000e-06
GCST001491_6Immune response to smallpox vaccine (IL-6)8.000000e-07
GCST001973_2Menarche (age at onset)3.000000e-06
GCST001973_4Menarche (age at onset)7.000000e-06
GCST002929_13Chromium levels8.000000e-06
GCST002945_5Emphysema imaging phenotypes8.000000e-07
GCST002963_4Post-traumatic stress disorder6.000000e-06
GCST003142_2Proteinuria in chronic kidney disease5.000000e-06
GCST004863_70Mosquito bite size2.000000e-06
GCST004863_71Mosquito bite size8.000000e-06
GCST005025_33Anti-saccade response9.000000e-06
GCST008154_39Trunk fat mass8.000000e-06
GCST009208_8Transverse temporal cortex volume1.000000e-06
GCST009391_588Metabolite levels7.000000e-06
GCST010396_257Gut microbiota (bacterial taxa, hurdle binary method)2.000000e-07
GCST012052_5Waist circumference5.000000e-08
GCST012616_19Spondylosis8.000000e-06
GCST90026414_4Severe insulin-resistant type 2 diabetes4.000000e-06

EFO canonical traits (8, from GWAS)

EFO IDTrait name
EFO:0003926neuropsychological test
EFO:0004645response to vaccine
EFO:0004703age at menarche
EFO:0007626emphysema imaging measurement
EFO:0008378mosquito bite reaction size measurement
EFO:0006874antisaccade response measurement
EFO:0010501indole-3-propionate measurement
EFO:0007874gut microbiome measurement

MeSH disease descriptors (3)

DescriptorNameTree numbers
D000544Alzheimer DiseaseC10.228.140.380.100; C10.574.945.249; F03.615.400.100
D003025ClubfootC05.330.488.655.063; C05.330.495.681.063; C05.660.585.512.380.813.063; C16.131.621.585.512.500.681.063
D052177Kidney Diseases, CysticC12.050.351.968.419.403; C12.200.777.419.403; C12.950.419.403

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

ChemicalActions (top 5)PubMed papers
Benzo(a)pyreneaffects methylation, increases mutagenesis2
bisphenol Aincreases methylation, affects cotreatment1
testosterone undecanoateincreases expression1
perfluorooctanoic acidaffects cotreatment, increases expression1
epigallocatechin gallateincreases expression1
perfluorooctane sulfonic acidaffects cotreatment, increases expression1
perfluorohexanesulfonic acidaffects cotreatment, increases expression1
Resveratrolaffects cotreatment, decreases expression1
Fulvestrantaffects cotreatment, increases methylation1
Caffeineincreases expression1
Demecolcinedecreases expression1
Ethyl Methanesulfonatedecreases expression1
Formaldehydedecreases expression1
Methyl Methanesulfonatedecreases expression1
Plant Extractsaffects cotreatment, decreases expression1
Aflatoxin B1increases methylation1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

TrialPhaseStatusTitle
NCT00009191PHASE4COMPLETEDThe Depression in Alzheimer’s Disease Study (DIADS)
NCT00009217PHASE4COMPLETEDTreatment of Behavioral Symptoms in Alzheimer’s Disease
NCT00018278PHASE4COMPLETEDElectrophysiologic Measures of Treatment Response in Alzheimer Disease
NCT00035204PHASE4COMPLETEDA Study of the Effects on Sleep, Attention, and Gastrointestinal Tolerance of Galantamine and Donepezil in Patients With Alzheimer’s Disease
NCT00042172PHASE4COMPLETEDTreatment for Early Memory Loss
NCT00046358PHASE4COMPLETEDThe Effect of Short-Term Statins and NSAIDs on Levels of Beta-Amyloid, a Protein Associated With Alzheimer’s Disease
NCT00104442PHASE4COMPLETEDStudy of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer’s Disease
NCT00120874PHASE4COMPLETEDMemantine and Comprehensive, Individualized Management of Alzheimer’s Disease and Caregiver Training
NCT00142324PHASE4UNKNOWNCALM-AD
NCT00165724PHASE4COMPLETEDAlzheimer’s Disease Long-term Follow-up Study (ALF Study)
NCT00165750PHASE4TERMINATEDCorrelation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients
NCT00202124PHASE4COMPLETEDDouble Blind Study of Trp01 in Patients With Alzheimer’s Disease
NCT00208819PHASE4COMPLETEDA Comparison of Two Standard Therapies in the Management of Dementia With Agitation
NCT00216515PHASE4COMPLETEDThe Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type
NCT00230568PHASE4COMPLETEDEARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer’s Disease (AD)
NCT00234637PHASE4COMPLETEDRivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer’s Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment
NCT00245206PHASE4COMPLETEDSide Effects of Newer Antipsychotics in Older Adults
NCT00254033PHASE4COMPLETEDApathy Associated With Alzheimer’s Disease
NCT00260624PHASE4COMPLETEDEscitalopram Treatment of Patients With Agitated Dementia
NCT00303277PHASE4COMPLETEDDo HMG CoA Reductase Inhibitors Affect Abeta Levels?
NCT00305903PHASE4COMPLETEDSafety and Tolerability of Rivastigmine With Add-on Memantine in Patients With Probable Alzheimer’s Disease
NCT00306124PHASE4UNKNOWNDopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
NCT00334906PHASE4COMPLETEDStudy of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer’s Disease)
NCT00369603PHASE4TERMINATEDFunctional Brain Imaging of Medication Treatment Response in Mild Alzheimer’s Disease Patients
NCT00375557PHASE4WITHDRAWNSafety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer’s Dementia Patients
NCT00381381PHASE4COMPLETEDThe Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer’s Disease
NCT00385684PHASE4COMPLETEDLow-Dose Opiate Therapy for Discomfort in Dementia (L-DOT)
NCT00401167PHASE4COMPLETEDMemantine for Agitation and Aggression in Severe Alzheimer’s Disease
NCT00403520PHASE4COMPLETEDHippocampus Study: Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers
NCT00417482PHASE4COMPLETEDAntipsychotic Discontinuation in Alzheimer’s Disease
NCT00443014PHASE4COMPLETEDThe Dementia Study in Northern Norway
NCT00469456PHASE4COMPLETEDEffect of Memantine on Functional Communication in Patients With Alzheimer’s Disease
NCT00476008PHASE4COMPLETEDDelaying the Progression of Driving Impairment in Individuals With Mild Alzheimer’s Disease
NCT00477659PHASE4COMPLETEDNeural Correlates In Mild Alzheimer’s Disease
NCT00480870PHASE4COMPLETEDThe Effect of Anticholinesterase Drugs on Sleep in Alzheimer’s Disease Patients
NCT00495820PHASE4COMPLETEDMethylphenidate for Apathy in Alzheimer’s Dementia: A Controlled Study
NCT00523666PHASE4UNKNOWNDiffusion Tensor Weighted MRI in Alzheimer’s Disease Modifying Treatment Effects of Galantamine (Reminyl®)
NCT00549601PHASE4COMPLETEDConvenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer’s Disease
NCT00551161PHASE4COMPLETEDMagnetic Resonance Spectroscopy Study of Memantine in Alzheimer’s Disease
NCT00561392PHASE4COMPLETEDClinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer’s Disease

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 74

This page pulls from 74 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot